Metabolic effects of nigrostriatal denervation in basal ganglia
- PMID: 11052224
- DOI: 10.1016/s1471-1931(00)00021-5
Metabolic effects of nigrostriatal denervation in basal ganglia
Abstract
In the past, functional changes in the circuitry of the basal ganglia that occur in Parkinson's disease were primarily analyzed with electrophysiological and 2-deoxyglucose measurements. The increased activity of the subthalamic nucleus (STN) observed has been attributed to a reduction in inhibition mediated by the external segment of the globus pallidus (GPe), secondary to the loss of dopaminergic-neuron influence on D2-receptor-bearing striato-pallidal neurons. More recently, in situ hybridization studies of cytochrome oxidase subunit I have confirmed the overactivity of the STN in the parkinsonian state. In addition, this technique has provided evidence that the change in STN activity is owing not only to decreased inhibition from the GPe but to hyperactivity of excitatory inputs from the parafascicular nucleus of the thalamus and the pedunculopontine nucleus in the brainstem.
Similar articles
-
Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA.J Neurosci. 1997 Jan 15;17(2):765-73. doi: 10.1523/JNEUROSCI.17-02-00765.1997. J Neurosci. 1997. PMID: 8987798 Free PMC article.
-
Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease.Neuroscience. 2000;97(1):79-88. doi: 10.1016/s0306-4522(00)00011-7. Neuroscience. 2000. PMID: 10771341
-
High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat.J Neurosci. 2002 Jun 15;22(12):5137-48. doi: 10.1523/JNEUROSCI.22-12-05137.2002. J Neurosci. 2002. PMID: 12077209 Free PMC article.
-
Anatomy of the dopamine system in the basal ganglia.Trends Neurosci. 2000 Oct;23(10 Suppl):S28-33. doi: 10.1016/s1471-1931(00)00023-9. Trends Neurosci. 2000. PMID: 11052217 Review.
-
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.Mov Disord. 2008;23 Suppl 3:S548-59. doi: 10.1002/mds.22062. Mov Disord. 2008. PMID: 18781672 Review.
Cited by
-
MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.Mol Neurobiol. 2018 Apr;55(4):2991-3006. doi: 10.1007/s12035-017-0559-6. Epub 2017 Apr 29. Mol Neurobiol. 2018. PMID: 28456940
-
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.J Neurosci. 2002 Jan 1;22(1):274-83. doi: 10.1523/JNEUROSCI.22-01-00274.2002. J Neurosci. 2002. PMID: 11756511 Free PMC article.
-
Therapeutic potential of targeting glutamate receptors in Parkinson's disease.J Neural Transm (Vienna). 2014 Aug;121(8):861-80. doi: 10.1007/s00702-014-1176-4. Epub 2014 Feb 21. J Neural Transm (Vienna). 2014. PMID: 24557498 Review.
-
Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease.Neurobiol Aging. 2007 Apr;28(4):568-78. doi: 10.1016/j.neurobiolaging.2006.02.010. Epub 2006 Mar 24. Neurobiol Aging. 2007. PMID: 16563567 Free PMC article.
-
The primate thalamostriatal systems: Anatomical organization, functional roles and possible involvement in Parkinson's disease.Basal Ganglia. 2011 Nov 1;1(4):179-189. doi: 10.1016/j.baga.2011.09.001. Basal Ganglia. 2011. PMID: 22773963 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous